Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma ; volume:7 ; number:1 ; day:7 ; month:11 ; year:2019 ; pages:1-11 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (7.11.2019), 1-11, 12.2019
- Urheber
-
Krimphove, Marieke J.
Tully, Karl H.
Friedlander, David F.
Marchese, Maya
Ravi, Praful
Lipsitz, Stuart R.
Kilbridge, Kerry L.
Kibel, Adam S.
Kluth, Luis A.
Ott, Patrick A.
Choueiri, Toni K.
Trinh, Quoc-Dien
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0782-y
- URN
-
urn:nbn:de:101:1-2020030419050983524599
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 01:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Krimphove, Marieke J.
- Tully, Karl H.
- Friedlander, David F.
- Marchese, Maya
- Ravi, Praful
- Lipsitz, Stuart R.
- Kilbridge, Kerry L.
- Kibel, Adam S.
- Kluth, Luis A.
- Ott, Patrick A.
- Choueiri, Toni K.
- Trinh, Quoc-Dien
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Predicting response to immunotherapy in metastatic melanoma by a personalized mathematical model
Immunotherapy of malignant melanoma
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Predicting response to immunotherapy in metastatic melanoma by a personalized mathematical model
Immunotherapy of malignant melanoma
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Predicting response to immunotherapy in metastatic melanoma by a personalized mathematical model
Immunotherapy of malignant melanoma
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy